Analysis of hearts from obese diabetic C57BL/KsJ-db/db mice following treatment with rosiglitazone, a medication for type 2 diabetes. Results provide insight into the molecular basis of the cardiac decompensation associated with both diabetes and rosiglitazone treatment.
Wilson KD, Li Z, Wagner R, Yue P et al. Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality. PLoS One 2008 Jul 9;3(7):e2609. PMID: 18648539
